// App-Quantinova.ai

5060 : Association of androgen receptor (AR) status in plasma DNA with outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC).

Researchers

Presenter

  • Vincenza Conteduca

Principal Investigators

  • Daniel Wetterskog

  • Mansour Taghavi Azar Sharabiani

  • Anuradha Jayaram

  • Samanta Salvi

  • Alessandro Romanel

  • Cristian Lolli

  • Valentina Casadio

  • Giorgia Gurioli

  • Dino Amadori

  • Delila Gasi Tandefelt

  • Anna Wingate

  • David P. Dearnaley

  • Francesca Demichelis

  • Ugo De Giorgi

  • Enrique Gonzalez-Billalabeitia

  • Gerhardt Attard

Medical Centers

  • Centre for Evolution and Cancer, The Institute of Cancer Research, London SW7 3RP, UK, London, United Kingdom

  • The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • St James Hospital, Kilmainhani, Ireland

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • University of Trento, Trento, Italy

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Centre for Integrative Biology, University of Trento, Trento, Italy

  • Department of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

Locations

  • Ireland

  • United Kingdom

  • Italy

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved